Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hutchmed (China)
HCM
5
Teradata Corp
TDC
US OptionsDetailed Quotes
MCRB250516C2500
- 0.00
- 0.000.00%
15min DelayTrading Apr 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover591.63%IV-75.30%PremiumMay 16, 2025Expiry Date7.62Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9524Delta0.0069Gamma1.31Leverage Ratio-0.0324Theta0.0009Rho1.25Eff Leverage0.0024Vega
Seres Therapeutics Newsroom
Seres Therapeutics Price Target Maintained With a $1.25/Share by Chardan Capital
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Piper Sandler Downgrades Seres Therapeutics(MCRB.US) to Hold Rating, Cuts Target Price to $1
Seres Therapeutics Analyst Ratings
Seres Therapeutics (MCRB) Gets a Hold From Piper Sandler
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics: Strategic Developments and Promising Clinical Data Justify Buy Rating
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics (MCRB) Receives a Buy From TD Cowen
Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics
Seres Therapeutics Analyst Ratings
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics (MCRB) Gets a Buy From TD Cowen
Seres Therapeutics Analyst Ratings
J.P. Morgan Downgrades Seres Therapeutics(MCRB.US) to Sell Rating
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now